<div><div></div><div>Fulcrum Therapeutics agreed to retention payments for Alex C. Sapir, Alan Musso and Curtis Oltmans and announced that Greg Tourangeau will depart as Vice President, Finance and principal accounting officer.<div><table><tbody><tr><td>Individual</td><td>Alex C. Sapir</td><td>Alan Musso</td><td>Curtis Oltmans</td><td>Greg Tourangeau</td></tr><tr><td>Role</td><td>President and Chief Executive Officer</td><td>Chief Financial Officer</td><td>Chief Legal Officer and Head of External Affairs</td><td>Vice President, Finance and principal accounting officer</td></tr><tr><td>Type of Change</td><td>Employment agreement amended; retention payment and enhanced Change in Control benefits</td><td>Employment agreement amended; retention payment and enhanced Change in Control benefits</td><td>Employment agreement amended; retention payment and enhanced Change in Control benefits</td><td>Departure agreed</td></tr><tr><td>Effective Date</td><td>June 5, 2026 (amendment); retention payable upon Change in Control or qualifying termination</td><td>June 11, 2026 (amendment); retention payable upon Change in Control or qualifying termination</td><td>June 5, 2026 (amendment); retention payable upon Change in Control or qualifying termination</td><td>June 10, 2026 (agreement to depart; actual departure date to be agreed)</td></tr><tr><td>Reason</td><td>Restructuring-related retention to preserve capital after discontinuation of pociredir development</td><td>Restructuring-related retention to preserve capital after discontinuation of pociredir development</td><td>Restructuring-related retention to preserve capital after discontinuation of pociredir development</td><td>Mutual agreement; not due to any disagreement over accounting or financial reporting</td></tr><tr><td>Replacement Info</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>To be agreed between Mr. Tourangeau and Fulcrum Therapeutics</td></tr><tr><td>Background Details</td><td>President and CEO; employment agreement filed as Exhibit 10.18 to 2025 10-K</td><td>Chief Financial Officer; employment agreement filed as Exhibit 10.19 to 2025 10-K</td><td>Chief Legal Officer and Head of External Affairs; employment agreement filed as Exhibit 10.20 to 2025 10-K</td><td>Vice President, Finance and principal accounting officer; departure mutually agreed</td></tr><tr><td>Board/Committee Role Changes</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td></tr></tbody></table></div>Original SEC Filing: Fulcrum Therapeutics, Inc. [ FULC ] - 8-K - Jun. 11, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

FULC

Fulcrum Therapeutics announced that Greg Tourangeau will depart as Vice President, Finance and principal accounting officer by mutual agreement. Concurrently, the company agreed to retention payments for CEO Alex Sapir, CFO Alan Musso, and Chief Legal Officer Curtis Oltmans. These measures aim to preserve capital following the discontinuation of pociredir development. The executive agreements include enhanced Change in Control benefits.

Fulcrum Therapeutics' Greg Tourangeau to Depart; Sapir, Musso and Oltmans Receive Retention Payments